JAPAN TOB 7/31/2025 Earnings Report

JAPAN TOB EPS Results

• Actual EPS: $0.32
• Consensus EPS: $0.25
• Beat/Miss: Beat by +$0.07
• One Year Ago EPS: N/A

JAPAN TOB Revenue Results

• Actual Revenue: $6.03 billion
• Expected Revenue: $896.47 billion
• Beat/Miss: Missed by -$890.44 billion
• YoY Revenue Growth: N/A

JAPAN TOB Announcement Details

• Date: 7/31/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

JAPAN TOB (OTCMKTS:JAPAY)acco Inc., trading as an American Depositary Receipt on the OTC market under the ticker OTCMKTS:JAPAY, is a global leader in the manufacturing and sale of tobacco and nicotine products. The company’s core portfolio includes well-known cigarette brands such as Mevius (formerly Mild Seven), Winston, Camel (under license), LD and Natural American Spirit. In response to shifting consumer preferences and regulatory pressures, Japan Tobacco has also developed heated tobacco units, e-vapor products and tobacco-free nicotine pouches.

Originally established in 1898 as a government monopoly, Japan Tobacco was privatized in 1985 and has since pursued a strategy of international expansion. Today, it conducts operations in more than 120 countries, with strong market positions across Asia, Europe, the Americas and Eastern Europe. Beyond tobacco, the company maintains a pharmaceutical segment focused on biopharmaceuticals, immunological therapies and vaccine development, as well as a food business that leverages its processing and distribution capabilities in select regions.

Headquartered in Tokyo, Japan Tobacco is overseen by an experienced board of directors and supported by an executive management team responsible for global strategy and operations. The company places emphasis on sustainability initiatives—addressing environmental impact, responsible marketing and community engagement—and continues to invest in product innovation and geographic diversification to adapt to the evolving regulatory landscape and changing consumer behaviors in the nicotine and pharmaceutical markets.